This morning the healthcare landscape restructures further as Novartis AG announced that it will purchase GlaxoSmithKline plc's cancer-drug business for $14.5 billion and will sell most of its vaccine business to GSK for $7.1 billion plus royalties. Simultaneously, Novartis announced the sale of its animal health division to Eli Lilly and Co. ( LLY ) for nearly $5.4 billion. Together Novartis and GSK will also create a joint venture in consumer healthcare, focusing on consumer healthcare with significant cash flow potential.